• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Theses
  • Research Data
  • Projects
  • Organizations
  • Researchers
  • More
  • Collections
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Swiss Recommendations for Cutaneous Basal Cell Carcinoma.

Swiss Recommendations for Cutaneous Basal Cell Carcinoma.

Details
Files
DOI
10.48350/173208
Publisher DOI
10.1159/000526478
PubMed ID
36137524
Abstract
Basal cell carcinoma (BCC) is the most common nonmelanoma skin cancer in Switzerland and worldwide. Most BCCs can be treated in a curative setting. However, patients can develop locally destructive and, rarely, metastatic tumors that require a different treatment approach. The clinical subtype of individual lesions provides prognostic information and influences management decisions. Surgical excision, topical therapies, and radiotherapy are highly effective in the majority of subtypes as well as in low- and high-risk diseases. For patients with low-risk diseases and superficial tumors not amenable to surgery, several nonsurgical alternatives are available. Systemic therapy is indicated for high-risk BCCs, which are not amenable to either surgery or radiotherapy. Hedgehog pathway inhibitors (HHI) are currently approved. Other therapeutic options such as immune checkpoint inhibitors show promising results in clinical trials. This first version of Swiss recommendations for diagnosis and management of BCC was prepared through extensive literature review and an advisory board consensus of expert dermatologists and oncologists in Switzerland. The present guidelines recommend therapies based on a multidisciplinary team approach and rate of recurrence for individual lesions. Based on the risk of recurrence, two distinct groups have been identified: low-risk (easy-to-treat) and high-risk (difficult-to-treat) tumors. Based on these classifications, evidence-based recommendations of available therapies are presented herein.
Date Issued
2023
Publication Type
Article
Subject(s)
600 Technology > 610 Medicine & health
Subjects
Basal cell carcinoma Hedgehog pathway inhibitors Locally advanced tumor Metastatic tumor PD-1 inhibitors
Language(s)
en
Author(s)
Ramelyte, Egle
Nägeli, Mirjam C
Hunger, Robert  
Universitätsklinik für Dermatologie  
Merat, Rastine
Gaide, Olivier
Navarini, Alexander A
Cozzio, Antonio
Wagner, Nikolaus B
Maul, Lara Valeska
Dummer, Reinhard
Additional Credits
Universitätsklinik für Dermatologie  
Journal
Dermatology
Publisher
Karger
ISSN
1018-8665
Access(Rights)
open.access
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: 0eaa7c [ 7.08. 11:06]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
  • Events
More
  • About BORIS Portal
  • BORIS Portal & Open Science
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo
Repository logo COAR Notify